Press Releases Kineta, Inc.

Equities

KA

US49461C1027

Market Closed - Nasdaq Other stock markets 21:00:00 21/06/2024 BST			5-day change	1st Jan Change
0.645 ^USD	+0.80%		+26.59%	-82.23%

05-15	Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kineta : Failure to Satisfy Listing Rule - Form 8-K	05-30	PU
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities	05-15	AQ
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial	04-08	AQ
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update	03-21	AQ
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported	03-12	AQ
Kineta Announces Restructuring and Exploration of Strategic Alternatives	02-29	AQ
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium	02-22	AQ
Kineta to Present at Upcoming Investor Conferences	02-14	AQ
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series	02-07	AQ
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors	01-17	AQ
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event	01-04	AQ
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer	12-13	AQ
Kineta to Present at the Life Sciences Investor Forum December 14th	12-12	AQ
Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023	11-28	AQ
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit	11-09	AQ
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	11-06	AQ
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update	11-03	AQ
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	11-03	AQ
Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors	17/10/23	AQ
Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023	12/10/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kineta, Inc.

Equities

KA

US49461C1027

Press Releases

Filters